Fierce Biotech4d
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
pharmaphorum28d
Boehringer drug for brain fog in schizophrenia fails trial
Boehringer Ingelheim's attempt to develop the first drug therapy for impaired cognitive function in schizophrenia, a core feature of the illness, has suffered what looks like a terminal setback.
Business Insider29d
Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...
Finanznachrichten29d
Boehringer Ingelheim Limited: Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...